A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 Administered Weekly Using a Fixed Dose Escalation Compared to Insulin Glargine in Insulin-Naïve Adults With Type 2 Diabetes
This study tests a new weekly insulin medication called insulin efsitora alfa to see how well it works compared to a standard daily insulin called insulin glargine. It aims to help adults with Type 2 diabetes who are starting insulin for the first time better manage their blood sugar levels.
You might be able to join if you are an adult with Type 2 diabetes who has never used insulin before, but needs to start because your blood sugar is not controlled by pills alone. You must also meet specific health guidelines and have stable blood sugar levels during screening.
Participants will be randomly assigned to receive either the new weekly insulin injection or the standard daily insulin injection. You will be closely monitored by the study team to track your blood sugar levels, overall health, and safety throughout the process.
This study has been completed and took place at multiple locations, including research centers in Alabama and California within the United States.
- 1Testing a new weekly insulin compared to a standard daily insulin
- 2Designed for adults with Type 2 diabetes starting insulin for the first time
- 3The study has successfully finished its trial run
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.